Tag: Sage Therapeutics

July 2, 2019 Off

ZULRESSO Launched by Sage Therapeutics, 11th FDA-approved drug to use Ligand’s Captisol technology

By BusinessWire

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that Sage Therapeutics has launched ZULRESSO™ (brexanolone) injection, which was approved by the U.S. Food and Drug Administration (FDA) on March 19, 2019, and is the first and only treatment specifically approved for postpartum depression (PPD), one of the most common medical complications during and after pregnancy.